IP Library Granted Patent US 7,183,051
Granted Patent B2
US 7,183,051 · App. 10/185,369 · Granted Feb 27, 2007

Diagnosis and treatment of cancer

Assignees: New England Medical Center; University of Mons-Hainaut
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,183,051
App. No.
10/185,369
Granted
Feb 27, 2007
Kind
B2
Abstract

The invention is based on the elucidation of a mechanism by which HPV promotes oncogenesis and provides a methods of diagnosing malignant tumors and methods of preventing the development of malignancies or inhibiting tumor growth. A method for diagnosing a neoplasm in a mammal is carried out by measuring the level of helicase-like transcription factor (HLTF) in tissue of the mammal. An increase in the level of HLTF in the tissue compared to the level in a normal control tissue indicates the presence of a neoplasm in the tissue.

Claims (7)

1. A method for diagnosing a breast neoplasm in a mammal, comprising measuring the level of helicase-like transcription factor (HLTF) in breast tissue of said mammal, wherein an increase in the level of HLTF in said tissue compared to the level in non-cancerous breast indicates the presence of a breast neoplasm in said tissue, wherein said measuring step comprises detecting a HLTF transcript in said tissue and wherein said transcript encodes the amino acid sequence of SEQ ID NO: 10.

2. A method for detecting the presence of a malignant breast tumor or a predisposition to developing said tumor, comprising contacting a sample of nucleic acid molecules obtained from a breast tissue biopsy with a nucleic acid probe which hybridizes under stringent conditions to a human HLTF nucleic acid transcript, wherein the transcript encodes the amino acid sequence of SEQ ID NO: 10, and determining the level of binding of said probe, wherein an increase in said binding compared to that in non-cancerous breast indicates the presence of a malignant breast tumor or a predisposition to developing said tumor, wherein said stringent conditions comprise a wash condition at 650° C. and a salt concentration of 0.1×SSC and wherein said probe comprises at least 15 nucleotides of SEQ ID NO: 9.

3. The method of claim 2 , wherein said probe comprises at least 30 nucleotides of SEQ ID NO:9.

4. The method of claim 2 , wherein said probe comprises at least 50 nucleotides of SEQ ID NO:9.

5. The method of claim 2 , wherein said probe comprises at least 100 nucleotides of SEQ ID NO:9.

6. The method of claim 2 , wherein said probe comprises at least 250 nucleotides of SEQ ID NO:9.

7. The method of claim 2 , wherein said probe comprises at least 500 nucleotides of SEQ ID NO:9.

Assignments (5)
CONFIRMATORY LICENSE Recorded Nov 17, 2021
From: TUFTS MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 058166/0879 →
CONFIRMATORY LICENSE Recorded Mar 6, 2019
From: TUFTS MEDICAL CENTER, INC.
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 048516/0790 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Jul 15, 2008
From: NEW ENGLAND MEDICAL CENTER HOSPITALS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021237/0199 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2002
From: ANDROPHY, ELLIOT J.; DOSHI, NISHITA
To: NEW ENGLAND MEDICAL CENTER
Reel/Frame 013373/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2002
From: BELAYEW, ALEXANDRA
To: MONS-HAINAUT, UNIVERSITY OF
Reel/Frame 013373/0661 →
Continuity (2)
Provisional Application 6030138400 · Jun 27, 2001
Related Publication 20030082526A1 · May 1, 2003